CN115197965A - Hpv疫苗 - Google Patents

Hpv疫苗 Download PDF

Info

Publication number
CN115197965A
CN115197965A CN202210614772.9A CN202210614772A CN115197965A CN 115197965 A CN115197965 A CN 115197965A CN 202210614772 A CN202210614772 A CN 202210614772A CN 115197965 A CN115197965 A CN 115197965A
Authority
CN
China
Prior art keywords
arenavirus
segment
viral vector
virus
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210614772.9A
Other languages
English (en)
Chinese (zh)
Inventor
克劳斯·奥尔林格
托马斯·莫纳思
安德斯·莉亚
莎拉·施密特
厄休拉·贝尔卡
迈克尔·史温丁格
伊丽莎白·沃森
贝蒂娜·基埃弗曼
朱莉娅·辛特拉姆斯科格勒
格哈德·富尔曼
安德列亚斯·埃斯珀克
凯瑟琳·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hookipa Biotech GmbH
Original Assignee
Hookipa Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech GmbH filed Critical Hookipa Biotech GmbH
Publication of CN115197965A publication Critical patent/CN115197965A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202210614772.9A 2015-06-10 2016-06-09 Hpv疫苗 Pending CN115197965A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562173805P 2015-06-10 2015-06-10
US62/173,805 2015-06-10
US201562254410P 2015-11-12 2015-11-12
US62/254,410 2015-11-12
US201662331158P 2016-05-03 2016-05-03
US62/331,158 2016-05-03
CN201680046208.4A CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗
PCT/EP2016/063182 WO2016198531A2 (en) 2015-06-10 2016-06-09 Hpv vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680046208.4A Division CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗

Publications (1)

Publication Number Publication Date
CN115197965A true CN115197965A (zh) 2022-10-18

Family

ID=56137292

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210614772.9A Pending CN115197965A (zh) 2015-06-10 2016-06-09 Hpv疫苗
CN201680046208.4A Active CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680046208.4A Active CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗

Country Status (8)

Country Link
US (3) US10669315B2 (https=)
EP (1) EP3307308A2 (https=)
JP (2) JP7098330B2 (https=)
CN (2) CN115197965A (https=)
AU (2) AU2016274655B2 (https=)
CA (1) CA2987155A1 (https=)
HK (1) HK1246183A1 (https=)
WO (1) WO2016198531A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604695T1 (sl) 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
SI3218504T1 (sl) 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US20200206334A1 (en) * 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
KR20200036873A (ko) * 2017-07-14 2020-04-07 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN108424925A (zh) * 2018-03-07 2018-08-21 江苏润洁生物科技有限公司 一种治疗性hpv核酸疫苗
MX2021005448A (es) * 2018-11-13 2021-08-11 Oncorus Inc Polinucleotidos encapsulados y metodos de uso.
JP7688576B6 (ja) * 2018-11-28 2025-07-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
WO2020255023A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
WO2021089853A1 (en) * 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
EP4059515A4 (en) * 2019-11-15 2024-02-14 Daiichi Sankyo Company, Limited Nucleic acid lipid particle vaccine encapsulating hpv mrna
BR112022022719A2 (pt) * 2020-05-14 2023-02-14 Inovio Pharmaceuticals Inc Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma
BR112022024404A2 (pt) * 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
WO2025155938A1 (en) * 2024-01-18 2025-07-24 Aov Biopharma, Inc. Vaccine for prevention and treatment of human papilloma virus related cancer
WO2025191169A1 (en) * 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用
CN118599010B (zh) * 2024-05-03 2025-06-27 武汉凯德基诺生物技术有限公司 一种hpv16/18/52治疗性疫苗、制备方法和应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012691A1 (fr) * 1998-08-27 2000-03-09 Fuso Pharmaceutical Industries, Ltd. Sequence d'acide nucleique utilisee pour potentialiser l'expression d'un gene utile et procede associe
CA2928263A1 (en) * 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
TW200631593A (en) * 2004-11-30 2006-09-16 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
CN101918565A (zh) * 2007-12-27 2010-12-15 苏黎士大学 复制缺陷型沙粒病毒载体
CN102002105A (zh) * 2009-09-03 2011-04-06 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2013151731A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US20140243256A1 (en) * 2013-02-26 2014-08-28 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
WO2020255023A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1553966B1 (en) * 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2013112549A1 (en) 2012-01-24 2013-08-01 Sanford Research/USD Polynucleotides for treating oncogenic viral polypeptide positive tumors
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
CN107109371A (zh) 2014-09-22 2017-08-29 明尼苏达大学评议会 皮钦德病毒反向遗传学系统及其使用方法
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
EP3365005B1 (en) 2015-10-23 2025-04-09 Institut Pasteur Recombinant mopeia virus and vaccine platform
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
IL262963B2 (en) 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2021089853A1 (en) 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
BR112022024404A2 (pt) 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012691A1 (fr) * 1998-08-27 2000-03-09 Fuso Pharmaceutical Industries, Ltd. Sequence d'acide nucleique utilisee pour potentialiser l'expression d'un gene utile et procede associe
CA2928263A1 (en) * 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
TW200631593A (en) * 2004-11-30 2006-09-16 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
CN101918565A (zh) * 2007-12-27 2010-12-15 苏黎士大学 复制缺陷型沙粒病毒载体
CN102002105A (zh) * 2009-09-03 2011-04-06 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2013151731A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US20140243256A1 (en) * 2013-02-26 2014-08-28 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
CN107223130A (zh) * 2014-11-13 2017-09-29 日内瓦大学 作为疫苗载体的三片段沙粒病毒
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
WO2020255023A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENSON YEE HIN CHENG等: "Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines", JOURNAL OF VIROLOGY, vol. 89, no. 14, 13 May 2015 (2015-05-13), pages 7373 - 7384, XP055239859, DOI: 10.1128/JVI.00307-15 *
LUKAS FLATZ等: "Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8 T cell immunity+", NATURE MEDICINE, vol. 16, 7 February 2010 (2010-02-07), pages 339 - 345, XP037922182, DOI: 10.1038/nm.2104 *
M.CRISTINA CASSETTI等: "Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes", VACCINE, vol. 22, no. 3, 31 January 2004 (2004-01-31), pages 520 - 527, XP004479374, DOI: 10.1016/j.vaccine.2003.07.003 *
SEBASTIEN E EMONET等: "Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies", VIROLOGY, vol. 411, no. 2, 15 February 2011 (2011-02-15), pages 416 - 425, XP028185472, DOI: 10.1016/j.virol.2011.01.013 *
SEBASTIEN F. EMONET等: "Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest", PNAS, vol. 106, no. 9, 3 March 2009 (2009-03-03), pages 3473 - 3478, XP055226314, DOI: 10.1073/pnas.0900088106 *
周彤: "减毒曼哥病毒:重组活疫苗的新载体", 国外医学.预防.诊断.治疗用生物制品分册, no. 06, 15 December 1996 (1996-12-15), pages 275 *

Also Published As

Publication number Publication date
CN107921117B (zh) 2022-06-07
AU2021232660A1 (en) 2021-10-07
JP2018518172A (ja) 2018-07-12
AU2016274655B2 (en) 2021-06-17
US11407790B2 (en) 2022-08-09
CN107921117A (zh) 2018-04-17
JP7098330B2 (ja) 2022-07-11
HK1246183A1 (zh) 2018-09-07
US20180179257A1 (en) 2018-06-28
WO2016198531A2 (en) 2016-12-15
US20210024584A1 (en) 2021-01-28
WO2016198531A3 (en) 2017-01-19
CA2987155A1 (en) 2016-12-15
JP2022160401A (ja) 2022-10-19
US20230086859A1 (en) 2023-03-23
AU2021232660B2 (en) 2025-02-27
EP3307308A2 (en) 2018-04-18
US10669315B2 (en) 2020-06-02
AU2016274655A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AU2021232660B2 (en) HPV vaccines
AU2014359276B2 (en) CMV vaccines
CN108779472B (zh) 针对乙型肝炎病毒的疫苗
US7318928B2 (en) Molecular vaccine linking intercellular spreading protein to an antigen
RU2644201C2 (ru) Вакцины против hpv
AU2017353443B2 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
CN110719788A (zh) 治疗实体瘤的沙粒病毒颗粒
JP2004500047A (ja) キメラ免疫原性組成物およびこれらをコードする核酸
US20070166328A1 (en) Genetic immunization against cervical carcinoma
KR102715320B1 (ko) 신형 hpv 치료용 핵산 백신
JP2019514988A (ja) 組合せプライム：ブースト療法
US20080260765A1 (en) HPV DNA Vaccines and Methods of Use Thereof
HK40082300A (en) Hpv vaccines
HK1263252B (en) Vaccines against hepatitis b virus
HK1263252A1 (en) Vaccines against hepatitis b virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082300

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221018

WD01 Invention patent application deemed withdrawn after publication